Burzynski Research Institute, Inc.

Equities

BZYR

US1231591058

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:47:19 2024-04-25 am EDT			5-day change	1st Jan Change
0.0428 ^USD	+2.32%		+64.62%	-2.73%

Jan. 16	Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	CI
2023	Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	CI

Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023

July 13, 2023 at 04:15 pm EDT

Burzynski Research Institute, Inc. reported earnings results for the first quarter ended May 31, 2023. For the first quarter, the company reported net loss was USD 0.287405 million compared to USD 0.231737 million a year ago.

Latest news about Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	Jan. 16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-12	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	23-07-13	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	23-05-25	CI
Burzynski Research Institute, Inc. Enters into A License Agreement with Dr. Stanislaw R. Burzynski	23-05-22	CI
Burzynski Research Institute, Inc. Announces Resignation of Carlton Hazlewood from the Board	23-04-06	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	23-01-13	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	22-10-13	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	22-07-14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	22-05-26	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	22-01-14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2021	21-10-15	CI
Burzynski Research Institute, Inc Announces Board Changes	21-10-06	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2021	21-05-24	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2020	21-01-14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2020	20-10-15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2020	20-07-15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2020	20-05-28	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2019	20-01-14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2019	19-10-15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2019	19-07-15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2019	19-05-29	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2018	19-01-14	CI
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma	16-04-14	CI
Burzynski Research Institute, Inc. Announces Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors - Final Report (Protocol Bt-09)	15-12-07	CI

Chart Burzynski Research Institute, Inc.

Duration

Period

Chart Burzynski Research Institute, Inc.

More charts

Company Profile

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BURZYNSKI RESEARCH INSTITUTE, INC.	-2.73%	5.62M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research